Stock listing

NASDAQ:MBIO Mustang Bio, Inc. Stock

Home listing (NASDAQ) of Mustang Bio, Inc.

Follow Mustang Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MBIO

$0.354 USD -0.026 (-6.8%)

Close on Nov 20, 2026

Past year -69.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.354 – $0.379 USDNov 20, 2026
Volume
84,286 sharesNov 20, 2026
Market cap
$2.38M USDAt the close on Nov 20, 2026 · price × 6.73M shares outstanding
52-week range
$0.350 – $1.430 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$14,807 USDMedian day 25,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Mustang Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MBIO · Home$0.354 USD-0.026 (-6.8%)84,286$0.379$0.379$0.354$0.380Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.354-0.026-6.8%$0.379$0.379$0.35484,286
$0.380-0.010-2.6%$0.390$0.396$0.3807,890
$0.390-0.005-1.2%$0.388$0.405$0.3859,350
$0.395-0.027-6.3%$0.417$0.421$0.38830,251
$0.421-0.043-9.3%$0.437$0.447$0.41619,408
$0.464+0.037+8.6%$0.445$0.479$0.42052,971
$0.428-0.023-5.1%$0.454$0.454$0.40928,203
$0.451+0.059+15.1%$0.410$0.489$0.389211,165
$0.391-0.003-0.8%$0.398$0.405$0.39118,528
$0.395+0.001+0.2%$0.400$0.406$0.39020,061
$0.394-0.020-4.8%$0.419$0.419$0.38030,157
$0.414+0.004+1.1%$0.413$0.418$0.4133,790
$0.409-0.006-1.3%$0.414$0.415$0.40314,424
$0.415+0.015+3.7%$0.401$0.426$0.40034,153
$0.400+0.008+1.9%$0.393$0.427$0.39048,267
$0.393+0.032+9.0%$0.385$0.405$0.37044,654
$0.360+0.001+0.2%$0.352$0.378$0.35124,835
$0.360-0.001-0.2%$0.357$0.385$0.35025,451
$0.360-0.010-2.7%$0.373$0.381$0.36010,244
$0.370+0.001+0.3%$0.390$0.391$0.36217,700
$0.369-0.014-3.7%$0.386$0.402$0.36929,200
$0.383+0.003+0.8%$0.388$0.401$0.37028,600
$0.380+0.007+1.9%$0.370$0.388$0.37010,200
$0.373-0.003-0.8%$0.372$0.385$0.3719,100
$0.376-0.010-2.6%$0.402$0.419$0.37130,000
$0.386+0.016+4.3%$0.370$0.392$0.37031,500
$0.370-0.007-1.9%$0.380$0.427$0.370159,800
$0.377-0.035-8.5%$0.394$0.396$0.37530,000
$0.412+0.012+3.0%$0.410$0.438$0.38154,400
$0.400-0.017-4.1%$0.434$0.434$0.38097,100
$0.417-0.033-7.3%$0.449$0.449$0.410101,100
$0.450-0.010-2.2%$0.456$0.460$0.45017,200
$0.4600.0000.0%$0.460$0.470$0.45543,300
$0.460-0.011-2.3%$0.460$0.466$0.46016,600
$0.471+0.004+0.9%$0.467$0.480$0.46033,400
$0.467+0.004+0.9%$0.468$0.468$0.45916,100
$0.463-0.017-3.5%$0.471$0.475$0.45828,600
$0.480-0.027-5.3%$0.503$0.507$0.47049,200
$0.507-0.013-2.5%$0.511$0.520$0.50412,100
$0.520-0.006-1.1%$0.525$0.525$0.5205,100
$0.526+0.015+2.9%$0.540$0.544$0.50139,000
$0.511-0.020-3.8%$0.487$0.550$0.48724,100
$0.531-0.019-3.5%$0.541$0.554$0.53118,900
$0.550+0.010+1.9%$0.530$0.558$0.53042,300
$0.540+0.050+10.2%$0.490$0.540$0.49052,500
$0.490-0.010-2.0%$0.511$0.511$0.48526,600
$0.500-0.004-0.8%$0.513$0.513$0.46641,800
$0.504-0.006-1.2%$0.545$0.545$0.50441,700
$0.510+0.003+0.6%$0.539$0.539$0.50720,500
$0.507-0.013-2.5%$0.532$0.550$0.50725,900
$0.520-0.008-1.5%$0.540$0.540$0.52020,600
$0.528-0.013-2.4%$0.552$0.552$0.5248,900
$0.541-0.002-0.4%$0.540$0.555$0.53322,500
$0.543-0.017-3.0%$0.553$0.558$0.53237,400
$0.560+0.017+3.1%$0.543$0.561$0.54329,900
$0.543-0.005-0.9%$0.550$0.550$0.54111,600
$0.548+0.010+1.9%$0.540$0.549$0.53718,100
$0.5380.0000.0%$0.538$0.540$0.5339,100
$0.538-0.012-2.2%$0.550$0.550$0.53020,300
$0.550-0.010-1.8%$0.560$0.560$0.54833,200
$0.560+0.008+1.4%$0.545$0.568$0.54515,800
$0.552+0.001+0.2%$0.551$0.577$0.5506,300
$0.551-0.028-4.8%$0.570$0.578$0.55031,800
$0.579+0.006+1.0%$0.573$0.579$0.5706,500
$0.573-0.001-0.2%$0.560$0.573$0.56014,200

Splits

2 splits since 2023 · NASDAQ:MBIO · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
1-for-15Consolidation
Ticker
NASDAQ:MBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

Latest news

All Mustang Bio, Inc. news

Mustang Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
123 in all · newest Jul 7, 2025 · oldest 2019
Decks
4 decks · latest February 2024

Where Mustang Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MBIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:MBIOBOATSUnited StatesUSD

Valuation

Price/book 0.4× against a median of 0.4×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$11.89M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
Median of the othersUS$2.40MUS$1.93M0.7×12.2×0.4×−301.9%0.1×1.30

Team and board

Officers

OfficerRole
Manuel LitchmanPresident, Chief Executive Officer and Director
Greg FurrowChief Quality Officer

Board

DirectorRole
Michael S. WeissChairman of the Board of Directors
Adam J. ChillDirector
David JinDirector
Lindsay A. RosenwaldDirector
Manuel LitchmanPresident, Chief Executive Officer and Director
Michael J. ZelefskyDirector
Neil HerskowitzDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026−15.0%
Q2 2026Aug 5, 2026−3.2%
Q1 2026May 29, 2026+21.3%
Q4 2025Mar 10, 2026+7.7%
Q3 2025Nov 7, 2025−2.4%
Q2 2025Aug 8, 2025+15.8%
Q1 2025May 13, 2025 · After close0.0%
Q4 2024Mar 28, 2025 · Before open−6.3%
Q3 2024Nov 8, 2024 · After close+0.8%
Q2 2024Aug 13, 2024 · After close−7.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close+8.5%
Q4 2023Mar 11, 2024 · After close−8.6%
Q3 2023Nov 14, 2023 · After close+2.9%
Q2 2023Aug 14, 2023 · After close−5.7%
Q1 2023May 12, 2023 · After close−6.7%
Q4 2022Mar 29, 2023 · After close+6.3%
Q3 2022Nov 14, 2022 · After close−2.3%
Q2 2022Aug 11, 2022 · After close+1.6%
Q1 2022May 12, 2022 · After close+5.6%
Q4 2021Mar 23, 2022 · After close+22.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2024)Investor deck47 slidesFebruary 2024
Investor Presentation (June 2017)Investor deck27 slidesJun 9, 2017
Investor Presentation (April 2016)Investor deck20 slidesApril 2016
Investor Presentation (March 2016)Investor deck20 slidesMarch 2016

Open Decks

Financings

RaiseDate
Public offering of common stock (or common stock equivalents) with Series C-1 and Series C-2 warrants
Closed: US$8M raised · US$3.01 a share · Warrants at US$3.01 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate and other purposes
Feb 10, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue41.0K823.0K2.23M3.03M2.31M1.78M1.37M630.0K2.00K0
Gross profit-41.0K-823.0K-2.23M-3.03M-2.31M-1.78M-1.37M-630.0K-2.00K0
Research and development1.52M7.56M40.5M62.5M49.9M37.2M30.0M2.10M100.0K2.00M
Selling, general and administrative3.95M4.13M9.69M12.2M11.0M9.51M9.57M6.76M11.4M2.82M
Operating income-2.43M-16.2M-49.3M-76.2M-66.7M-56.8M-45.9M-31.2M-31.8M-11.4M
Depreciation and amortization34.0K671.0K1.86M2.72M2.17M1.68M1.26M630.0K2.00K0
EBITDA-2.40M-15.6M-47.4M-73.4M-64.6M-55.1M-44.6M-30.6M-31.8M-11.4M
Interest expense5.00K4.11M3.36M15.0K3.92M1.77M8.00K8.00K895.0K
Income before tax-1.92M-15.8M-51.6M-77.5M-66.4M-60.0M-46.4M-30.7M-31.3M-12.7M
Income tax27.0K-15.8M1.37M-2.29M2.13M1.77M569.0K505.0K23.9M
Net income-1.92M-15.8M-51.6M-77.5M-66.4M-60.0M-46.4M-30.7M-31.3M-12.7M
Earnings per share, basic-0.39-38.57-299.95-10.09-0.76-1.14-1.29-1.14-1.24-1.15
Earnings per share, diluted-0.39-38.57-299.95-10.09-0.76-1.14-1.29-1.14-1.24-1.15

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents17.3M6.84M6.23M75.7M109.6M97.8M61.4M16.5M35.5M27.5M
Short-term investments017.6M26.0M0
Receivables217.0K402.0K3.88M299.0K50.0K15.0K19.0K37.0K106.0K
Inventory00
Current assets17.6M8.61M11.3M78.9M111.7M99.5M63.1M35.1M61.4M27.5M
Property, plant and equipment0371.0K3.25M8.44M11.1M8.03M7.94M6.86M1.38M0
Goodwill00
Total assets17.6M9.31M17.7M92.4M125.2M109.9M73.4M42.8M63.5M27.5M
Accounts payable3.51M7.46M6.32M6.83M3.51M3.52M1.88M1.39M3.47M683.0K
Current liabilities7.91M12.6M15.4M15.1M10.8M9.52M7.77M5.62M3.61M3.22M
Long-term debt27.4M12.2M00
Total debt878.0K2.50M31.4M2.03M2.23M15.5M320.0K
Total liabilities8.06M13.2M17.6M46.1M12.8M11.5M21.8M6.36M3.66M3.22M
Shareholders' equity9.53M-3.87M123.0K46.3M112.4M98.4M51.7M36.4M59.8M24.3M
Shares outstanding4.91M6.13M8.60M6.90M93.6M70.9M39.4M26.6M25.2M15.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.26M-11.4M-49.5M-65.1M-53.7M-37.3M-33.6M-19.2M-12.9M-4.13M
Capital spending00-64.0K-2.71M-3.99M-1.93M-2.35M-6.87M-424.0K-424.0K
Free cash flow-5.26M-11.4M-49.5M-67.8M-57.7M-39.2M-35.9M-26.1M-13.4M-4.13M
Cash from investing1.17M05.89M-2.95M-5.37M-4.41M13.9M557.0K-29.1M0
Cash from financing14.5M11.3M-26.1M34.1M70.8M78.1M65.1M181.0K50.0M31.6M
Dividends paid-273.0K-611.0K-477.0K-320.0K0
Share buybacks923.0K35.2M29.5M181.0K1.68M35.0M
Change in cash10.4M-145.0K-69.7M-34.0M11.8M36.4M45.4M-18.5M7.98M27.5M

Open Financials

Filings

FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementNov 20, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansNov 5, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportOct 15, 2026Current reportSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
8-K · Current reportApr 17, 2026Current reportSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 5, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
8-K · Current reportDec 23, 2025Meeting outcomeSEC
DEF 14A · Proxy statementDec 3, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 1, 2025Big-stake noticeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
424B5 · ProspectusSep 5, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportJul 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
4 · Change in ownershipApr 28, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 14, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 4, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2025Big-stake noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
POS EXApr 1, 2025Other filingsSEC
424B3 · ProspectusApr 1, 2025Offer documentSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 5, 2025Current reportSEC
DEF 14CMar 3, 2025Meeting noticeSEC
424B3 · ProspectusFeb 27, 2025Offer documentSEC
8-K · Current reportFeb 27, 2025Acquisition or disposalSEC
PRE 14CFeb 21, 2025Meeting noticeSEC
8-K · Current reportFeb 21, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
424B3 · ProspectusFeb 13, 2025Offer documentSEC
8-K · Current reportFeb 13, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
8-K · Current reportFeb 11, 2025Material contractSEC
424B4 · ProspectusFeb 7, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 5, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 5, 2025Offer documentSEC
DEF 14CJan 22, 2025Meeting noticeSEC
UPLOAD · Letter from the SECJan 20, 2025Other filingsSEC
8-K · Current reportJan 17, 2025Current reportSEC
S-1 · Registration statementJan 15, 2025Offer documentSEC
PRE 14CJan 10, 2025Meeting noticeSEC
8-K · Current reportJan 10, 2025Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 3, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJan 3, 2025Insider tradeSEC
8-K · Current reportJan 2, 2025Meeting outcomeSEC
DEF 14A · Proxy statementDec 6, 2024Meeting noticeSEC
424B3 · ProspectusDec 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 29, 2024Other filingsSEC
CORRESP · Letter to the SECNov 25, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 25, 2024Other filingsSEC
S-3 · Registration statementNov 22, 2024Offer documentSEC
8-K · Current reportNov 15, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024Current reportSEC
3 · Initial statement of ownershipOct 29, 2024Insider tradeSEC
8-K · Current reportOct 25, 2024Material contractSEC
8-K · Current reportSep 13, 2024Current reportSEC
424B5 · ProspectusAug 16, 2024Offer documentSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJul 30, 2024Other filingsSEC
CORRESP · Letter to the SECJul 25, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 25, 2024Other filingsSEC
S-1 · Registration statementJul 19, 2024Offer documentSEC
DEF 14CJul 10, 2024Meeting noticeSEC
8-K · Current reportJul 3, 2024Acquisition or disposalSEC
424B5 · ProspectusJul 3, 2024Offer documentSEC
PRE 14CJun 28, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedJun 28, 2024Big-stake noticeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
DJun 21, 2024Other filingsSEC
8-K · Current reportJun 21, 2024Material contractSEC
424B5 · ProspectusJun 21, 2024Offer documentSEC
424B5 · ProspectusJun 20, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 13, 2024Other filingsSEC
CORRESP · Letter to the SECJun 10, 2024Other filingsSEC
8-K · Current reportJun 6, 2024Material contractSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
UPLOAD · Letter from the SECJun 4, 2024Other filingsSEC
S-3 · Registration statementMay 31, 2024Offer documentSEC
8-K · Current reportMay 21, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
424B3 · ProspectusMay 13, 2024Offer documentSEC
8-K · Current reportMay 2, 2024Material contractSEC
424B4 · ProspectusMay 1, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
CORRESP · Letter to the SECApr 29, 2024Other filingsSEC
S-1/A · Registration statement, amendedApr 29, 2024Offer documentSEC
S-1/A · Registration statement, amendedApr 29, 2024Offer documentSEC
8-K · Current reportApr 29, 2024ResultsSEC
CORRESP · Letter to the SECApr 29, 2024Other filingsSEC
CORRESP · Letter to the SECApr 29, 2024Other filingsSEC
S-1/A · Registration statement, amendedApr 29, 2024Offer documentSEC
8-K · Current reportApr 12, 2024Current reportSEC
S-1/A · Registration statement, amendedApr 2, 2024Offer documentSEC
8-K · Current reportMar 29, 2024Current reportSEC
UPLOAD · Letter from the SECMar 20, 2024Other filingsSEC
S-1 · Registration statementMar 15, 2024Offer documentSEC
8-K · Current reportMar 15, 2024Current reportSEC
8-K · Current reportMar 11, 2024ResultsSEC
10-K · Annual reportMar 11, 2024Annual reportSEC
8-K · Current reportFeb 14, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
3 · Initial statement of ownershipFeb 12, 2024Insider tradeSEC
8-K · Current reportJan 25, 2024Management or board changeSEC
8-K · Current reportJan 4, 2024Current reportSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 19, 2023Insider tradeSEC
UPLOAD · Letter from the SECDec 18, 2023Other filingsSEC
S-1 · Registration statementDec 11, 2023Offer documentSEC
8-K · Current reportDec 11, 2023Management or board changeSEC
8-K · Current reportDec 11, 2023Current reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
DNov 3, 2023Other filingsSEC
8-K · Current reportNov 2, 2023Current reportSEC
8-K · Current reportOct 30, 2023Material contractSEC
424B5 · ProspectusOct 30, 2023Offer documentSEC
8-K · Current reportOct 26, 2023Current reportSEC
8-K · Current reportOct 4, 2023Current reportSEC
UPLOAD · Letter from the SECSep 6, 2023Other filingsSEC
CORRESP · Letter to the SECAug 28, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 23, 2023Other filingsSEC
8-K · Current reportAug 16, 2023Current reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
S-8 · Registration statement for employee plansJul 31, 2023Offer documentSEC
8-K · Current reportJul 31, 2023Acquisition or disposalSEC
8-K · Current reportJul 20, 2023Material contractSEC
8-K · Current reportJul 11, 2023Current reportSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
8-K · Current reportJun 30, 2023Material contractSEC
8-K · Current reportJun 23, 2023Management or board changeSEC
8-K · Current reportMay 22, 2023Material contractSEC
8-K · Current reportMay 12, 2023ResultsSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 20, 2023Current reportSEC
424B5 · ProspectusApr 14, 2023Offer documentSEC
8-K · Current reportApr 13, 2023Current reportSEC
3/A · Initial statement of ownership, amendedApr 6, 2023Insider tradeSEC
3/A · Initial statement of ownership, amendedApr 6, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
8-K · Current reportApr 3, 2023Current reportSEC
10-K · Annual reportMar 29, 2023Annual reportSEC
8-K · Current reportMar 29, 2023ResultsSEC
DEF 14CMar 13, 2023Meeting noticeSEC
PRE 14CMar 3, 2023Meeting noticeSEC
8-K · Current reportMar 3, 2023Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedJan 13, 2023Big-stake noticeSEC
4 · Change in ownershipJan 6, 2023Insider tradeSEC
8-K · Current reportDec 13, 2022Material contractSEC
8-K · Current reportNov 25, 2022Current reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportAug 11, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
S-8 · Registration statement for employee plansJul 15, 2022Offer documentSEC
SC 13G · Big-stake noticeJul 8, 2022Big-stake noticeSEC
8-K · Current reportJul 7, 2022Current reportSEC
8-K · Current reportJun 24, 2022Management or board changeSEC
3 · Initial statement of ownershipJun 7, 2022Insider tradeSEC
8-K · Current reportMay 31, 2022Current reportSEC
8-K · Current reportMay 12, 2022ResultsSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
DEFA14A · Additional proxy materialApr 29, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2022Meeting noticeSEC
8-K · Current reportApr 22, 2022Management or board changeSEC
PRE 14A · Preliminary proxy statementApr 19, 2022Meeting noticeSEC
8-K · Current reportMar 23, 2022ResultsSEC
10-K · Annual reportMar 23, 2022Annual reportSEC
8-K · Current reportMar 17, 2022Management or board changeSEC
8-K · Current reportMar 8, 2022Material contractSEC
SC 13G · Big-stake noticeFeb 4, 2022Big-stake noticeSEC

This page holds 200 of 406 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Mustang Bio, Inc.’s releases · as of Feb 10, 2025

Common shares
6,732,121
Fully diluted
6,732,121

Fully diluted

LineShares
Common shares6,732,121

Warrants and options

Lot
Warrants · US$3.01 · expiry not stated

Share count over time

CountShares
Nov 22, 20266,732,121

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Kestra Advisory Services, LLC163K2.4%US$75,293Sep 30, 2026
BlackRock84,7451.3%US$39,237Sep 30, 2026
Citadel70,0621.0%US$32,439Sep 30, 2026
Vanguard57,8240.86%US$26,773Sep 30, 2026
Geode Capital40,6300.60%US$18,811Sep 30, 2026
CFO4Life Group, LLC33,5100.50%US$15,515Sep 30, 2026
XTX Topco Ltd12,9860.19%US$6,013Sep 30, 2026
StoneX Group Inc.11,6040.17%US$6,143Sep 30, 2026
Tower Research Capital LLC (TRC)1,8860.03%US$873Sep 30, 2026
UBS6920.01%US$320Sep 30, 2026
All 20 holders
HolderSharesOf the companyValueAs of
SBI Securities Co., Ltd.509<0.01%US$236Sep 30, 2026
Morgan Stanley118<0.01%US$55Sep 30, 2026
Cullen/Frost Bankers, Inc.13<0.01%US$6Sep 30, 2026
Global Retirement Partners, LLC11<0.01%US$5Sep 30, 2026
BNP Paribas6<0.01%US$3Sep 30, 2026
Lanark Financial, Inc.3<0.01%US$1Sep 30, 2026
Danske Bank A/S2<0.01%US$1Sep 30, 2026
Fidelity2<0.01%US$1Sep 30, 2026
JPMorgan2<0.01%US$1Sep 30, 2026
Osaic Holdings, Inc.2<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund84,1441.2%US$56,385May 31, 2026
Vanguard Extended Market Index Fund25,7040.38%US$18,044Jun 30, 2026
Fidelity Series Total Market Index Fund4,1840.06%US$2,804May 31, 2026
Fidelity Total Market Index Fund1,0770.02%US$722May 31, 2026
Nomura Healthcare Fund160<0.01%US$112Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Fortress Biotech, Inc.8.00%537KJan 2, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael S. Weiss
Other companies: Checkpoint Therapeutics Inc (Director · Since at least Sep 9, 2016); Fortress Biotech, Inc. (Executive Vice Chairman, Strategic Development · Since at least Jan 1, 2016); TG Therapeutics, Inc. (Chairman, President, and Chief Executive Officer · Since at least Dec 31, 2015); Avenue Therapeutics, Inc. (Director · Mar 13, 2017 – Aug 7, 2018 · Past); National Holdings Corporation (Director · Sep 12, 2016 – Sep 12, 2016 · Past)
Chairman of the Board of Directors · Since at least Sep 26, 2016
Lindsay A. Rosenwald
Other companies: Avenue Therapeutics, Inc. (Director · Since at least Sep 23, 2024); Checkpoint Therapeutics Inc (Director · Since at least May 14, 2024); Journey Medical Corporation (Chairman · Since at least Mar 22, 2024); Fortress Biotech, Inc. (Chairman, President and Chief Executive Officer · Since at least Nov 14, 2023)
Director · Since at least Nov 5, 2026
Neil Herskowitz
Other companies: Journey Medical Corporation (Director · Since at least Nov 16, 2021); Checkpoint Therapeutics Inc (Director · Since at least Jun 14, 2018); Avenue Therapeutics, Inc. (Director · Since at least Oct 9, 2017); National Holdings Corporation (Director · Feb 12, 2018 – Feb 12, 2018 · Past)
Director · Since at least Jun 14, 2018
David Jin
Other companies: Avenue Therapeutics, Inc. (Interim Chief Financial Officer and Chief Operating Officer · Since at least Nov 5, 2026); Fortress Biotech, Inc. (Chief Financial Officer and Head of Corporate Development · Since at least Apr 1, 2026)
Director · Since at least Nov 5, 2026
James B Murphy
Other companies: Decibel Therapeutics Inc (See Remarks · Oct 7, 2022 – Oct 7, 2022 · Past)
Interim CFO · Jan 19, 2024 – Jan 19, 2024 · Past
Adam J. ChillDirector · Since at least Dec 30, 2025
Greg FurrowChief Quality Officer · Since at least Nov 4, 2026
Manuel LitchmanPresident, Chief Executive Officer and Director · Since at least Apr 24, 2017
Michael J. ZelefskyDirector · Since at least Jul 29, 2022

Open People

Log in to ask 6ix AI your own questions about Mustang Bio, Inc.